Valuation : Easton Pharmaceuticals Inc.

Market Cap 269K 232K 219K 199K 373K 25.7M 375K 2.61M 1M 13.07M 1.01M 988K 41.31M P/E 2019
-4.17x
P/E 2020 -4.29x
Enterprise Value 2.75M 2.37M 2.24M 2.03M 3.82M 263M 3.84M 26.66M 10.25M 134M 10.33M 10.11M 423M EV / Sales 2019
6.27x
EV / Sales 2020 -
Free-Float
97.34%
Yield 2019 *
-
Yield 2020 -
21-12-22 Parallel Industries Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2021 CI
19-09-26 Easton Pharmaceuticals Inc. cancelled the acquisition of Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada. CI
19-06-13 Easton Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019 CI
19-04-30 Easton Pharmaceuticals Inc. Moves its Corporate Head Office CI
19-04-25 Easton Pharmaceuticals Inc. acquired Supreme Sweets Inc. from Barbara and Mario Parravano. CI
19-03-27 Easton Pharmaceuticals Inc. Signs LOI with Licensed Producer of Cannabis to Expand its Operations and Participate in its Cannabis Edibles Division CI
19-03-10 Easton Pharmaceuticals Inc. Commences Cannabis Edibles Division CI
19-02-05 Easton Pharmaceuticals Inc. Announces Updates on its $2,600,000 Framing Contract to Construct 150 Homes as Well as Other Initiatives CI
19-01-23 Easton Pharmaceuticals Inc. Announces Sales Results for the Quarter Ended September 30, 2018 and December 31, 2018 CI
19-01-11 Easton Pharmaceuticals Inc. Provides Operational Update on CAD 2,600,000 Framing Contract CI
19-01-02 Easton Pharmaceuticals Announces Signing and Commencement of CAD 2,600,000 Framing Contract to Construct 150 Homes CI
18-11-28 Gunpowder Capital Corp. cancelled the acquisition of iBliss Inc. from Easton Pharmaceuticals Inc.. CI
18-09-26 Easton Pharmaceuticals Inc. signed a letter of intent to acquire Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada. CI
Manager TitleAgeSince
Chief Executive Officer - 2015-06-29
Chief Operating Officer - 2018-06-19
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Director/Board Member - 2015-06-29
Director/Board Member - 2018-06-19
Change 5-day change 1-year change 3-year change Capi.($)
+30.43%+27.78% - - 1.34K
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average +2.77%-2.95%+30.65%+247.47% 30.05B
Weighted average by Cap. -0.56%-2.83%+31.25%+170.65%

Financials

2019 2020
Net sales 1.56M 1.34M 1.27M 1.15M 2.16M 149M 2.17M 15.07M 5.8M 75.61M 5.84M 5.71M 239M -
Net income -323K -278K -264K -239K -448K -30.87M -451K -3.13M -1.2M -15.71M -1.21M -1.19M -49.63M -189K -162K -154K -139K -262K -18.01M -263K -1.83M -703K -9.16M -708K -693K -28.96M
Net Debt 8.41M 7.25M 6.86M 6.22M 11.67M 804M 11.73M 81.5M 31.34M 409M 31.59M 30.9M 1.29B 2.48M 2.14M 2.03M 1.84M 3.44M 237M 3.46M 24.05M 9.25M 121M 9.32M 9.12M 381M
Logo Easton Pharmaceuticals Inc.
Parallel Industries Inc., formerly Easton Pharmaceuticals, Inc., is a development-stage company engaged in various pharmaceutical sectors and other industries. The Company has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The Company owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The Company's products are in various stages of commercialization. The Company's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!